[url="]Schall, Brown and Schwartz LLP[/url] (“SBS”), a national shareholder rights litigation fi

LOS ANGELES--(BUSINESS WIRE)---- $ARDX--ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securi

[url="]Faruqi and Faruqi, LLP[/url], a leading national securities law firm, is investigating potent

NEW YORK--(BUSINESS WIRE)---- $ARDX #ARDX--Faruqi & Faruqi, LLP, a leading national securities law f

NEW YORK, Sept. 18, 2026 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities c

New class action for Ardelyx, Inc. (ARDX) urges investors to seek recovery for alleged securities fr

Faruqi & Faruqi, LLP Securities Litigation Partner  James (Josh) Wilson Encourages Investors Who Suf

SAN DIEGO--(BUSINESS WIRE)---- $ARDX #Ardelyx--Shareholder rights law firm Robbins LLP informs inves

ATLANTA, Sept. 18, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed agains

Ardelyx (NASDAQ:ARDX) released second-quarter financial results and hosted an earnings call on Thurs

NEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsi

Ardelyx, Inc. (ARDX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Ardelyx, Inc. (NASDAQ: ARDX - Get Free Report) shares hit a new 52-week low during trading on Wednes

WALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “C

Freestone Grove Partners LP bought a new position in Ardelyx, Inc. (NASDAQ: ARDX) in the undefined q

Ardelyx shares fell nearly 18% on August 7, 2026 after the Company cut its full-year IBSRELA revenue

Piper Sandler analyst Christopher Raymond maintains Ardelyx (NASDAQ:ARDX) with a Overweight and l

Every 100 shares of Ardelyx (NASDAQ: ARDX) held into August 7, 2026 lost about $87 in value as the s

NEW YORK--(BUSINESS WIRE)--Every 100 shares of Ardelyx (NASDAQ: ARDX) held into August 7, 2026 lost

Ardelyx cut its 2026 IBSRELA revenue guidance by up to $80 million on August 6, 2026, citing payer u

Ardelyx Investigation Notice: Levi and Korsinsky Notifies Investors of Pending Investigation Into Ar

ARDX closed at $4.00 on August 7, 2026 -- down 17.86% -- after Q2 product revenue of $118.1 million

Citigroup analyst Yigal Nochomovitz maintains Ardelyx (NASDAQ:ARDX) with a Buy and lowers the pri

TD Cowen analyst Joseph Thome maintains Ardelyx (NASDAQ:ARDX) with a Buy and lowers the price tar

BTIG analyst Julian Harrison maintains Ardelyx (NASDAQ:ARDX) with a Buy and lowers the price targ

Gainers Doximity (NYSE:DOCS) stock rose 85.1% to $38.25 during Friday's pre-market session. The

US stock futures mixed, Nasdaq 100 futures up 100 points. Trade Desk Inc shares down 27.7% after wea

Atlassian Corp (NASDAQ: TEAM) reported strong Q4 results, beating revenue and earnings estimates. St

Gainers Doximity (NYSE:DOCS) stock increased by 65.6% to $34.22 during Thursday's after-market

Ardelyx (NASDAQ:ARDX) reported quarterly losses of $(0.07) per share which missed the analyst consen

Ladenburg Thalmann analyst Caroline Palomeque assumes Ardelyx (NASDAQ:ARDX) with a Buy rating and

XPHOZAH is the first and only phosphate absorption inhibitor (PAI) approved by the U.S. Food and Dru

Ardelyx (NASDAQ:ARDX) reported quarterly losses of $(0.15) per share which missed the analyst consen

Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commerciali